{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:05Z","timestamp":1790391185741,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672686"],"award-info":[{"award-number":["81672686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04103-0","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T23:04:37Z","timestamp":1746486277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Qihua","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"10192","key":"4103_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380.","journal-title":"Lancet"},{"issue":"1","key":"4103_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12916-023-03140-x","volume":"21","author":"Y Fang","year":"2023","unstructured":"Fang Y, Su N, Zou Q, Cao Y, Xia Y, Tang L, Tian X, Liu P, Cai Q. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. BMC Med. 2023;21(1):423.","journal-title":"BMC Med"},{"issue":"29","key":"4103_CR3","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","volume":"33","author":"AW Lee","year":"2015","unstructured":"Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356\u201364.","journal-title":"J Clin Oncol"},{"issue":"29","key":"4103_CR4","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/JCO.21.00396","volume":"39","author":"S Hong","year":"2021","unstructured":"Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J, Wu X, Huang Y, Yang Y, Lin Q, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study. J Clin Oncol. 2021;39(29):3273\u201382.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4103_CR5","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536\u201343.","journal-title":"Nat Med"},{"issue":"8","key":"4103_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162\u201374.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4103_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.oraloncology.2005.01.008","volume":"41","author":"DT Chua","year":"2005","unstructured":"Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005;41(6):589\u201395.","journal-title":"Oral Oncol"},{"issue":"10054","key":"4103_CR8","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883\u201392.","journal-title":"Lancet"},{"issue":"6","key":"4103_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","volume":"110","author":"J Schlessinger","year":"2002","unstructured":"Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110(6):669\u201372.","journal-title":"Cell"},{"issue":"1","key":"4103_CR10","doi-asserted-by":"publisher","first-page":"e12003","DOI":"10.1002\/jev2.12003","volume":"10","author":"F Li","year":"2020","unstructured":"Li F, Zhao X, Sun R, Ou J, Huang J, Yang N, Xu T, Li J, He X, Li C, et al. EGFR-rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K\/AKT pathway-suppressed ROS. J Extracell Vesicles. 2020;10(1):e12003.","journal-title":"J Extracell Vesicles"},{"issue":"10","key":"4103_CR11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/hed.23481","volume":"36","author":"W Sun","year":"2014","unstructured":"Sun W, Long G, Wang J, Mei Q, Liu D, Hu G. Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis. Head Neck. 2014;36(10):1508\u201316.","journal-title":"Head Neck"},{"issue":"14","key":"4103_CR12","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1158\/0008-5472.CAN-08-4518","volume":"69","author":"A Talavera","year":"2009","unstructured":"Talavera A, Friemann R, G\u00f3mez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, L\u00f3pez-Requena A, Pupo A, Johansen RF, S\u00e1nchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"4103_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00002371-200303000-00006","volume":"26","author":"T Crombet","year":"2003","unstructured":"Crombet T, Torres L, Neninger E, Catal\u00e1 M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, P\u00e9rez R, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003;26(2):139\u201348.","journal-title":"J Immunother"},{"issue":"7","key":"4103_CR14","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s12094-020-02522-4","volume":"23","author":"L Qu","year":"2021","unstructured":"Qu L, Wang JH, Du JX, Kang P, Niu XQ, Yin LZ. Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2. Clin Transl Oncol. 2021;23(7):1342\u20139.","journal-title":"Clin Transl Oncol"},{"key":"4103_CR15","doi-asserted-by":"publisher","first-page":"175883592095373","DOI":"10.1177\/1758835920953738","volume":"12","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Yang S, Zhou S, Yang J, Qin Y, Gui L, Shi Y, He X. Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol. 2020;12:1758835920953738.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"4103_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/annonc\/mdz020","volume":"30","author":"C Zhao","year":"2019","unstructured":"Zhao C, Miao J, Shen G, Li J, Shi M, Zhang N, Hu G, Chen X, Hu X, Wu S, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann Oncol. 2019;30(4):637\u201343.","journal-title":"Ann Oncol"},{"key":"4103_CR17","doi-asserted-by":"publisher","first-page":"571304","DOI":"10.3389\/fonc.2020.571304","volume":"10","author":"Y Ueda","year":"2020","unstructured":"Ueda Y, Enokida T, Okano S, Fujisawa T, Ito K, Tahara M. Combination treatment with paclitaxel, carboplatin, and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic nasopharyngeal carcinoma. Front Oncol. 2020;10:571304.","journal-title":"Front Oncol"},{"key":"4103_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3389\/fonc.2020.01011","volume":"10","author":"M Zhang","year":"2020","unstructured":"Zhang M, Huang H, Li X, Huang Y, Chen C, Fang X, Wang Z, Guo C, Lam S, Fu X, et al. Long-term survival of patients with chemotherapy-na\u00efve metastatic nasopharyngeal carcinoma receiving cetuximab plus docetaxel and cisplatin regimen. Front Oncol. 2020;10:1011.","journal-title":"Front Oncol"},{"issue":"2","key":"4103_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"6","key":"4103_CR20","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.20099","volume":"100","author":"JY Shao","year":"2004","unstructured":"Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100(6):1162\u201370.","journal-title":"Cancer"},{"issue":"1","key":"4103_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"9","key":"4103_CR22","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/annonc\/mdv268","volume":"26","author":"J Guigay","year":"2015","unstructured":"Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015;26(9):1941\u20137.","journal-title":"Ann Oncol."},{"issue":"10","key":"4103_CR23","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/ijc.32380","volume":"145","author":"R You","year":"2019","unstructured":"You R, Liu YP, Lin M, Huang PY, Tang LQ, Zhang YN, Pan Y, Liu WL, Guo WB, Zou X, et al. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer. 2019;145(10):2873\u201383.","journal-title":"Int J Cancer"},{"issue":"7","key":"4103_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704\u201312.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4103_CR25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/annonc\/mdf200","volume":"13","author":"RK Ngan","year":"2002","unstructured":"Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, Kwok CH, Chiu CY, Au SK, Foo W, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13(8):1252\u20138.","journal-title":"Ann Oncol"},{"issue":"9","key":"4103_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/jjco\/hyv083","volume":"45","author":"JC Hsieh","year":"2015","unstructured":"Hsieh JC, Hsu CL, Ng SH, Wang CH, Lee KD, Lu CH, Chang YF, Hsieh RK, Yeh KH, Hsiao CH, et al. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective phase II trial. Jpn J Clin Oncol. 2015;45(9):819\u201327.","journal-title":"Jpn J Clin Oncol"},{"issue":"20","key":"4103_CR27","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961\u201370.","journal-title":"JAMA"},{"issue":"6","key":"4103_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, Chen X, Sun Y, He X, Hu C, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061-72.e4.","journal-title":"Cancer Cell"},{"issue":"14","key":"4103_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4103_CR30","doi-asserted-by":"publisher","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhou T, Chen X, Li J, Pan J, He X, Lin L, Shi YR, Feng W, Xiong J, et al. Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9(12):e003790.","journal-title":"J Immunother Cancer"},{"key":"4103_CR31","doi-asserted-by":"publisher","first-page":"102136","DOI":"10.1016\/j.eclinm.2023.102136","volume":"62","author":"N Lu","year":"2023","unstructured":"Lu N, Jiang YF, Xia WX, Huang Y, Xie CM, Xu C, Ye YF, Liu GY, Bei WX, Ke LR, et al. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study. EClinicalMedicine. 2023;62:102136.","journal-title":"EClinicalMedicine"},{"issue":"14","key":"4103_CR32","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/JCO.22.01450","volume":"41","author":"X Ding","year":"2023","unstructured":"Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, Peng L, Liu YP, Duan CY, Yang Q, et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study. J Clin Oncol. 2023;41(14):2571\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4103_CR33","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","volume":"14","author":"L Yuan","year":"2023","unstructured":"Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, et al. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nat Commun. 2023;14(1):4893.","journal-title":"Nat Commun"},{"issue":"12","key":"4103_CR34","doi-asserted-by":"publisher","first-page":"101833","DOI":"10.1016\/j.xcrm.2024.101833","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zou Q, Zhao B, Su N, Li Z, Wang X, Liu P, Tian X, Fang X, Cai J, et al. Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm phase 2 trial (TORAL). Cell Rep Med. 2024;5(12):101833.","journal-title":"Cell Rep Med"},{"key":"4103_CR35","first-page":"59","volume":"2","author":"M Takeda","year":"2011","unstructured":"Takeda M, Okamoto I, Nishimura Y, Nakagawa K. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. Lung Cancer (Auckl). 2011;2:59\u201367.","journal-title":"Lung Cancer (Auckl)"},{"issue":"1732","key":"4103_CR36","doi-asserted-by":"publisher","first-page":"20160270","DOI":"10.1098\/rstb.2016.0270","volume":"372","author":"SW Tsao","year":"2017","unstructured":"Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160270.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"24","key":"4103_CR37","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461\u201370.","journal-title":"N Engl J Med"},{"issue":"11","key":"4103_CR38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cac2.12100","volume":"40","author":"R Tan","year":"2020","unstructured":"Tan R, Phua SKA, Soong YL, Oon LLE, Chan KS, Lucky SS, Mong J, Tan MH, Lim CM. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun (Lond). 2020;40(11):564\u201385.","journal-title":"Cancer Commun (Lond)"},{"issue":"6","key":"4103_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"4103_CR40","doi-asserted-by":"publisher","first-page":"e220587","DOI":"10.1001\/jamanetworkopen.2022.0587","volume":"5","author":"JY Xu","year":"2022","unstructured":"Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, Chen JL, Wang YQ, Han F, Wang FH. Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open. 2022;5(3):e220587.","journal-title":"JAMA Netw Open"},{"key":"4103_CR41","doi-asserted-by":"publisher","first-page":"714433","DOI":"10.3389\/fonc.2021.714433","volume":"11","author":"L Zhu","year":"2021","unstructured":"Zhu L, Ouyang T, Xiong Y, Ba L, Li Q, Qiu M, Zou Z, Peng G. Prognostic value of plasma Epstein-Barr virus DNA levels pre- and post-neoadjuvant chemotherapy in patients with nasopharyngeal carcinoma. Front Oncol. 2021;11:714433.","journal-title":"Front Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04103-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T06:02:53Z","timestamp":1746511373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04103-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center (B2018-097). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}